Citric acid

Evofem Biosciences to Report Second Quarter 2022 Results and Provide Corporate Update on Thursday, August 4, 2022

Retrieved on: 
Thursday, July 28, 2022

SAN DIEGO, July 28, 2022 /PRNewswire/ -- Evofem Biosciences, Inc., (Nasdaq: EVFM) will hold a webcast and conference call to discuss financial results and business highlights for the second quarter ended June 30, 2022 as follows:

Key Points: 
  • If participating by phone, please dial in approximately 15 minutes prior to the start of the call.
  • Evofem Biosciences, Inc., (Nasdaq: EVFM) is developing and commercializing innovative products to address unmet needs in women's sexual and reproductive health, including hormone-free, woman-controlled contraception and protection from chlamydia and gonorrhea.
  • The Company's first FDA-approved product,Phexxi(lactic acid, citric acid and potassium bitartrate), is ahormone-free, on-demand prescription contraceptive vaginal gel.
  • It comes in a box of 12 pre-filled applicators and is applied 0-60 minutes before each act of sex.

Evofem's House Rules Campaign Featuring Annie Murphy Receives Significant Industry Recognition

Retrieved on: 
Tuesday, July 26, 2022

SAN DIEGO, July 26, 2022 /PRNewswire/ -- Evofem Biosciences, Inc.,(Nasdaq: EVFM)announced today a series of industry awards and recognition for the company's direct-to-consumer (DTC) advertising campaign, House Rules.

Key Points: 
  • SAN DIEGO, July 26, 2022 /PRNewswire/ -- Evofem Biosciences, Inc.,(Nasdaq: EVFM)announced today a series of industry awards and recognition for the company's direct-to-consumer (DTC) advertising campaign, House Rules.
  • House Rules features Emmy Award-winning spokeswoman Annie Murphy, who shares her personal birth control journey and the many reasons why Phexxi is the right contraceptive for her.
  • "I'm so proud of what we have been able to accomplish with House Rules," said Annie Murphy, acclaimed actress and Phexxi user and spokeswoman.
  • "The House Rules campaign and our partnership with Annie Murphy has furthered this goal by raising awareness of Phexxi with millions of women.

Evofem Biosciences Unveils New Educational Birth Control Chart to Assist Providers in Patient Contraceptive Counseling

Retrieved on: 
Monday, July 25, 2022

"Contraceptive counseling is one of the most important aspects of a healthcare provider's job.

Key Points: 
  • "Contraceptive counseling is one of the most important aspects of a healthcare provider's job.
  • "Choosing the right birth control method should be an informed one and this chart recognizes the latest innovations in contraception."
  • The new educational chart presents an overview of twelve birth control methods that are currently available in the U.S.
  • Healthcare providers wishing to receive posters of the new birth control chart may download here, https://www.evofem.com/wp-content/uploads/2022/07/EVFM-US-001984-Contrac... or contact their local Phexxi sales representative.

Evofem Biosciences Applauds U.S. House of Representatives for Passing The Right to Contraception Act

Retrieved on: 
Friday, July 22, 2022

SAN DIEGO, July 22, 2022 /PRNewswire/ -- Evofem Biosciences, Inc., (Nasdaq: EVFM), a women's healthcare company, today applauded the 228 members of the U.S. House of Representatives who voted to pass legislation to safeguard access to contraceptives entitled The Right to Contraception Act.

Key Points: 
  • SAN DIEGO, July 22, 2022 /PRNewswire/ -- Evofem Biosciences, Inc., (Nasdaq: EVFM), a women's healthcare company, today applauded the 228 members of the U.S. House of Representatives who voted to pass legislation to safeguard access to contraceptives entitled The Right to Contraception Act.
  • "Today we applaud the U.S. House of Representatives for passing The Right to Contraception Act, which would codify into law the fundamental right to safe and easy access to contraception," saidSaundra Pelletier, Chief Executive Officer of Evofem Biosciences.
  • Providing women with their choice of contraception should not be up for debate."
  • Evofem Biosciences, Inc., (Nasdaq: EVFM) is developing and commercializing innovative products to address unmet needs in women's sexual and reproductive health, including hormone-free, woman-controlled contraception and protection from chlamydia and gonorrhea.

Evofem Partners with a360 Media to Support Phexxi® Prescription Growth

Retrieved on: 
Thursday, July 21, 2022

SAN DIEGO, July 21, 2022 /PRNewswire/ -- Evofem Biosciences, Inc., (Nasdaq: EVFM) today announced an agreement between Evofem and a360 Media under which Phexxi® (lactic acid, citric acid, and potassium bitartrate) branded content will appear in some of the most widely read entertainment and lifestyle magazines and websites in the U.S.

Key Points: 
  • a360 Media reaches 60 million unique digital visitors per month and another 27 million via print audiences.
  • One out of every three a360 Media readers and digital users is a female between the ages of 18 and 34, making this partnership an ideal union.
  • To date, 72% of the prescriptions through the Phexxi telehealth program are to women in this demographic.
  • After the first two weeks of the partnership, new prescriptions of Phexxi - a hormone-free, on-demand prescription contraceptive vaginal gel - were up 16%.

Global Citric Acid Market Analysis, Trends, Market Size, and Forecasts 2022-2028: Continuously Rising Demand for Citric Acid for Food Additives & Animal Feed - ResearchAndMarkets.com

Retrieved on: 
Tuesday, July 19, 2022

The "Citric Acid Market: Global Industry Analysis, Trends, Market Size, and Forecasts up to 2028" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Citric Acid Market: Global Industry Analysis, Trends, Market Size, and Forecasts up to 2028" report has been added to ResearchAndMarkets.com's offering.
  • The report on the global citric acid market provides qualitative and quantitative analysis for the period from 2020 to 2028.
  • The report on citric acid market is a comprehensive study and presentation of drivers, restraints, opportunities, demand factors, market size, forecasts, and trends in the global citric acid market over the period of 2020 to 2028.
  • Complete coverage of all the segments in the citric acid market to analyze the trends, developments in the global market and forecast of market size up to 2028.

Phexxi® Mechanism of Action Article Published in the Journal of Therapeutic Advances in Reproductive Health

Retrieved on: 
Tuesday, July 12, 2022

SAN DIEGO, July 12, 2022 /PRNewswire/ -- Evofem Biosciences, Inc.,(Nasdaq: EVFM)announced today that theJournal of Therapeutic Advances in Reproductive Health has published Mechanisms of action of currently available woman-controlled, vaginally administered, non-hormonal contraceptive products , a peer-reviewed article defining and reconfirming the mechanism of action (MOA) of Phexxi (lactic acid, citric acid, potassium bitartrate).

Key Points: 
  • SAN DIEGO, July 12, 2022 /PRNewswire/ -- Evofem Biosciences, Inc.,(Nasdaq: EVFM)announced today that theJournal of Therapeutic Advances in Reproductive Health has published Mechanisms of action of currently available woman-controlled, vaginally administered, non-hormonal contraceptive products , a peer-reviewed article defining and reconfirming the mechanism of action (MOA) of Phexxi (lactic acid, citric acid, potassium bitartrate).
  • "Our society benefits when women have choices and access to the best contraception for their lives and bodies.
  • The publication in the Journal of Therapeutic Advances in Reproductive Healthmarks the second peer-reviewed journal to publish Phexxi data in 2022.
  • Earlier this year, the Journal of Sexual Medicine published sexual satisfaction data showing that 88.7% of women using Phexxi improved or maintained their sex life.

Evofem Strengthens Phexxi® Intellectual Property with New Composition of Matter Patent From USPTO

Retrieved on: 
Thursday, June 30, 2022

With the issuance of this patent, in the United States, Evofem will solely have the right to make, have made, market, and sell for any commercial purpose the composition of matter that comprises Phexxi.

Key Points: 
  • With the issuance of this patent, in the United States, Evofem will solely have the right to make, have made, market, and sell for any commercial purpose the composition of matter that comprises Phexxi.
  • "We are pleased to receive this new patent, which further builds on our composition of matter protection and while already well-protected by more than 40 patents, this allowance further solidifies the investment Evofem has made in creating Phexxi and providing it to women across the United States," said Saundra Pelletier, Chief Executive Officer of Evofem.
  • "This patent allowance is a clear nod to the innovation Phexxi brings to contraception and a woman's ability to protect herself from unintended pregnancies."
  • The Company does not undertake any duty to update any forward-looking statement except as required by law.

Evofem Reaches Agreement with One of the Largest Pharmacy Benefit Managers in the U.S. for Access to Phexxi®

Retrieved on: 
Tuesday, June 28, 2022

"This new agreement removes existing barriers, allowing women in the U.S. covered by this plan to fill their Phexxi prescriptions immediately," said Saundra Pelletier, Chief Executive Officer of Evofem.

Key Points: 
  • "This new agreement removes existing barriers, allowing women in the U.S. covered by this plan to fill their Phexxi prescriptions immediately," said Saundra Pelletier, Chief Executive Officer of Evofem.
  • The agreement comes as Evofem continues building upon earlier successes and lining up further access through other health insurers and PBMs to increase a woman's ability to obtain Phexxi.
  • Evofem continues to support these steps aimed at protecting women's access to Phexxi.
  • "Evofem's sales force continues updating doctors and their offices about these new agreements, paving the way for easier access to Phexxi," said Katherine Atkinson, Chief Commercial Officer of Evofem.

Gelesis Announces Additional $15 Million Pre-Order for Plenity®, Bringing Total Pre-Paid Orders from Ro for Plenity to $55 Million

Retrieved on: 
Tuesday, June 21, 2022

This is in addition to previous Plenity pre-orders from Ro totaling $40 million.

Key Points: 
  • This is in addition to previous Plenity pre-orders from Ro totaling $40 million.
  • This is in addition to previous Plenity pre-orders from Ro totaling $40 million.
  • Since the broad consumer launch, Plenity has become one of the most sought-after offerings on Ros platform.
  • The treatment is then shipped directly to their home and arrives within 2 days, at $98 for a 28-day supply.